EVLO OTC
Cambridge, MA 02139
US
Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Bodmer Mark | S-Sale | 3,163 | $0.33 | 2023-11-08 |
| McHale Duncan | S-Sale | 3,103 | $0.33 | 2023-11-08 |
| GILL SIMBA | S-Sale | 172 | $0.33 | 2023-11-08 |
| Thorell Marella | S-Sale | 1,811 | $0.33 | 2023-11-08 |
| Bodmer Mark | M-Exempt | 6,625 | — | 2023-11-07 |